explore -WSS

explore

author：leisure time 2025-09-27 09:44:54 - browse：27

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Why palliative psychiatry is worth discussing

entertainment

WSS

STAT readers on older presidents, polypills, Medicare, and more

American TikTok star stuck in Dubai for months following rental car altercation

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

New documents shed light on MD Anderson Cancer Institute feud

Antivenom research: Lessons from HIV applied in search for universal antidote

American TikTok star stuck in Dubai for months following rental car altercation

entertainment

explore

Wikipedia

Heart attack and stroke risk calculators need revising

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

'Weather

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Alkermes shareholders re

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

United colonoscopy coverage change 'may cost lives,' doctors say

A new nitrogen execution bill also undermines medical licensing

leisure time

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

New documents shed light on MD Anderson Cancer Institute feud

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

What AstraZeneca

Sudan conflict brings new atrocities to Darfur as militias kill, rape, burn homes in rampages

Alabama hospital puts IVF treatments on hold

hotspot

entertainment

focus

knowledge